GSK’s chairman of R&D discusses late-stage therapies

Moncef Slaoui

Moncef Slaoui, the chairman of research and development at GlaxoSmithKline, recently touted the advanced and innovative nature of therapies in the company’s late-stage pipeline.

Slaoui discussed the highly innovative therapies in the company’s late-stage pipeline with more verve than some of the drugs under review that could hit the market even sooner. Slaoui referred to GSK’s late-stage cancer immunotherapy MAGE-A3 as one of the company’s breakthrough innovations, Dow Jones Newswires reports.

GSK advanced MAGE-A3 into separate Phase III trials for patients with non-small cell lung cancer and melanoma. The company anticipates initial results from one of the studies as early as late 2013.

Another drug Slaoui discussed was darapladib, an add-on LpPLA2 enzyme statin-blocker from Human Genome Sciences. GSK has 14 late-stage programs with results anticipated over the next couple years with six drugs under regulatory review.

Some of the other therapies under review for GSK, including the once-weekly GLP1 diabetes drug albiglutide, are not first-in-class and face competition from established drugs that are already on the market, according to Dow Jones Newswires.

One major impending review is Breo, a once-daily respiratory treatment that faces an FDA panel on March 7 and potential approval in May. The company is looking to sustain its respiratory business after patents for twice-daily Advair fizzle.

Breo is under the microscope to determine its effectiveness in comparison to other treatments for smoker’s cough, asthma and chronic obstructive pulmonary disease.

This story filed in Medical Countermeasures, Vaccine Development and tagged . Bookmark the permalink.

Comments are closed.